CNBC – HOME

Regeneron’s Technical Reversal Signals 15% Upside Potential

Regeneron Pharmaceuticals is showing a significant technical reversal pattern according to market analysis. The large-cap biotech stock could see 15% upside if the pattern completes as projected.

by Darren HoltOctober 31, 2025November 3, 2025

Business Startups Technology

Navan’s IPO Stumble Reveals Corporate Travel’s Rocky Road

Navan’s Nasdaq debut saw shares fall 12% despite a successful $923 million IPO. The corporate travel platform’s valuation dropped $3 billion from its 2022 private funding round, highlighting market concerns.

by Natalie BrooksOctober 30, 2025November 2, 2025